Pro-inflammatory cytokines in chronic cardiac failure: state of problem
- 作者: Korotaeva A.1, Samoilova E.1, Mindzaev D.1, Nasonova S.1, Zhirov I.1,2, Tereschenko S.1,2
-
隶属关系:
- National Medical Research Center for Cardiology
- Russian Medical Academy of Continuing Professional Education
- 期: 卷 93, 编号 11 (2021)
- 页面: 1389-1394
- 栏目: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/99726
- DOI: https://doi.org/10.26442/00403660.2021.11.201170
- ID: 99726
如何引用文章
全文:
详细
Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.
作者简介
Alexandra Korotaeva
National Medical Research Center for Cardiology
Email: erihter@mail.ru
ORCID iD: 0000-0003-3687-7085
д-р биол. наук, рук. лаб. биохимии воспалительных процессов атерогенеза ФГБУ «НМИЦ кардиологии»
俄罗斯联邦, MoscowElena Samoilova
National Medical Research Center for Cardiology
编辑信件的主要联系方式.
Email: erihter@mail.ru
ORCID iD: 0000-0003-1396-5736
канд. мед. наук, вед. науч. сотр. лаб. биохимии воспалительных процессов атерогенеза ФГБУ «НМИЦ кардиологии»
俄罗斯联邦, MoscowDzambolat Mindzaev
National Medical Research Center for Cardiology
Email: erihter@mail.ru
ORCID iD: 0000-0002-2236-3959
аспирант отд. сердечной недостаточности и заболеваний миокарда ФГБУ «НМИЦ кардио- логии»
俄罗斯联邦, MoscowSvetlana Nasonova
National Medical Research Center for Cardiology
Email: erihter@mail.ru
ORCID iD: 0000-0002-0920-7417
канд. мед. наук, ст. науч. сотр. отд. сердечной недостаточности и заболеваний миокарда ФГБУ «НМИЦ кардиологии»
俄罗斯联邦, MoscowIgor Zhirov
National Medical Research Center for Cardiology; Russian Medical Academy of Continuing Professional Education
Email: erihter@mail.ru
ORCID iD: 0000-0002-4066-2661
д-р мед. наук, вед. науч. сотр. отд. сердечной недостаточности и заболеваний миокарда ФГБУ «НМИЦ кардиологии», проф. каф. кардиологии ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowSergei Tereschenko
National Medical Research Center for Cardiology; Russian Medical Academy of Continuing Professional Education
Email: erihter@mail.ru
ORCID iD: 0000-0001-9234-6129
д-р мед. наук, проф., рук. отд. сердечной недостаточности и заболеваний миокарда ФГБУ «НМИЦ кардиологии», зав. каф. кардиологии ФГБОУ ДПО РМАНПО
俄罗斯联邦, Moscow参考
- Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74 [Tereshchenko SN, Galyavich AS, Uskach TM, et al. Clinical practice guidelines for Chronic heart failure 2020. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian)]. doi: 10.15829/1560-4071-2020-4083
- Ponikowski P, Voors AA, Anker DS, et al. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017;1(141):7-81 [Ponikowski P, Voors AA, Anker DS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;1(141):7-81 (in Russian)]. doi: 10.15829/1560-4071-2017-1-7-81
- Li Z, Zhao H, Wang J. Metabolism and chronic inflammation: the links between chronic heart failure and comorbidities. Front Cardiovasc Med. 2021;8:650278. doi: 10.3389/fcvm.2021.650278
- Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81-101. doi: 10.1146/annurev.physiol.65.092101.142249
- Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-68. doi: 10.1161/CIRCRESAHA.116.302317
- Hanna A, Frangogiannis NG. inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34(6):849-63. doi: 10.1007/s10557-020-07071-0
- Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55(19):2129-37. doi: 10.1016/j.jacc.2009.12.045
- van Wijk SS, van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006-14. doi: 10.1002/ejhf.414
- Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092
- Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. doi: 10.1093/eurheartj/ehx564
- Van Linthout S, Tschope СC. inflammation – cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251-65. doi: 10.1007/s11897-017-0337-9
- Gullestad L, Ueland T, Fjeld JG, et al. Effect ofthalidomide oncardiac remodelinginchronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112(22):3408-14. doi: 10.1161/CIRCULATIONAHA.105.564971
- Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083-8. doi: 10.1161/01.cir.103.8.1083
- Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. doi: 10.1161/01.cir.103.2.220
- Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40. doi: 10.1161/01.CIR.0000077913.60364.D2
- Mann DL, McMurray J, Packer M, et al. Targeted аnticytokine therapy in patients with chronic yeart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602. doi: 10.1161/01.CIR.0000124490.27666.B2
- Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371(9608):228-36. doi: 10.1016/S0140-6736(08)60134-8
- Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914
- Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(8):e005036. doi: 10.1161/CIRCHEARTFAILURE.118.005036
- Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 Blockade Inhibits the Acute Inflammatory response in patients with st-segment-elevation myocardial infarction. Am J Cardiol. 2020;9(5):e014941. doi: 10.1161/JAHA.119.014941
- Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36:377-84. doi: 10.1093/eurheartj/ehu272
- Yan AT, Yan RT, Cushman M, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31(7):875-82. doi: 10.1093/eurheartj/ehp454
- Harhay MO, Tracy RP, Bagiella E, et al. Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study. Int J Cardiol. 2013;168(4):3818-24. doi: 10.1016/j.ijcard.2013.06.028
- Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62-8. doi: 10.1016/j.cyto.2014.12.024
- Wu JW, Hu H, Li D, Ma LK. Hypoxia-inducible factor 2-alpha-dependent induction of IL-6 protects the heart from ischemia/reperfusion injury. Aging (Albany NY). 2021;13(3):3443-58. doi: 10.18632/aging.202276
- Smart N, Mojet MH, Latchman DS, et al. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69:164-77. doi: 10.1016/j.cardiores.2005.08.017
- Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004;64:61-71. doi: 10.1016/j.cardiores.2004.05.011
- Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145-55. doi: 10.1161/CIRCULATIONAHA.109.933127
- Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS medicine. 2008;5:e78. doi: 10.1371/journal.pmed.0050078
- Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-54. doi: 10.1182/blood.V86.4.1243.bloodjournal8641243
- Yamamoto K, Rose-John S. Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease. Clin Pharmacol Ther. 2012;91(4):574-6. doi: 10.1038/cplt.2012.11
- Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-36. doi: 10.1189/jlb/1105674
- Askevold ET, Gullestad L, Dahl CP, et al. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11(2):146-55. doi: 10.1007/s11897-014-0185-9
- Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160-7. doi: 10.1046/j.1432-1327.2001.01867.x
- Чепурнова Д.А., Самойлова Е.В., Анисимов А.А., и др. Компоненты рецепторного комплекса интерлейкина-6 при остром повреждении легких. Бюллетень экспериментальной биологии и медицины. 2018;164(5):609-11 [Chepurnova DA, Samoilova EV, Anisimov AA, et al. Compounds of IL-6 receptor complex during acute lung injury. Bull Exp Biol Med. 2018;164(5):609-11 (in Russian)]. doi: 10.1007/s10517-018-4042-9
- Korotaeva AA, Samoilova EV, Chepurnova DA, et al. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers. 2018;23(2):1-18. doi: 10.1080/1354750X.2018.1458151
- Zhou M, Dai W, Cui Y, et al. Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women. Ann Transl Med. 2020;8(6):379-90. doi: 10.21037/atm.2020.02.27
- Самойлова Е.В., Миндзаев Д.Р., Чепурнова Д.А., и др. Циркулирующий гликопротеин 130 у пациентов с различной степенью выраженности симптомов хронической сердечной недостаточности. Кардиологический вестник. 2019;3:57-61 [Samoilova EV, Mindzaev DR, Chepurnova DA, et al. Circulating glycoprotein 130 in patients with chronic heart failure of varying symptom degrees. Kardiologicheskii vestnik. 2019;3:57-61 (in Russian)]. doi: 10.36396/MS.2019.14.03.009
- Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19(5):237-41. doi: 10.1007/s00380-004-0770-z
- Askevold ET, Nymo S, Ueland T, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013;6(1):91-8. doi: 10.1161/CIRCHEARTFAILURE.112.972653
- McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021:9(6):643-54. doi: 10.1016/S2213-2600(21)00103-X
- Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375-83. doi: 10.1172/JCI57158
- Rabe B, Chalaris A, May U. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021-8. doi: 10.1182/blood-2007-07-102137